Sodium-glucose cotransporter-2 inhibitors (SGLT2is), a cornerstone of T2DM management, confer cardioprotective effects that may involve microbiota-mediated pathways. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.